Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | TNKS | O95271 | 14/20 | 0.38 |
| ▸ | PARP1 | P09874 | 14/20 | 0.38 |
| ▸ | TNKS2 | Q9H2K2 | 14/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | INMT | O95050 | 1/20 | 0.33 |
| ▸ | TYMP | P19971 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26018436 | 0.82 | POLB (0.40) | POLBTNKSPARP1TNKS2HPGD | |
| SCHEMBL20955537 | 0.80 | TNKS (0.34) | TNKSPARP1TNKS2HPGD | |
| SCHEMBL20954788 | 0.80 | TNKS (0.51) | TNKSPARP1TNKS2 | |
| SCHEMBL20955731 | 0.77 | TNKS (0.43) | TNKSPARP1TNKS2 | |
| SCHEMBL26018420 | 0.72 | HPRT1 (0.36) | POLBTNKSPARP1TNKS2HPGD | |
| SCHEMBL18689727 | 0.65 | HPGD (0.50) | POLBTNKSPARP1TNKS2HPGD | |
| SCHEMBL3425926 | 0.65 | HPGD (0.53) | POLBTNKSPARP1TNKS2HPGD | |
| SCHEMBL29310289 | 0.62 | ALDH1A1 (0.36) | INMT | |
| SCHEMBL22058384 | 0.62 | HRH4 (0.31) | TNKSPARP1TNKS2 | |
| SCHEMBL26018017 | 0.62 | TNKS (0.48) | TNKSPARP1TNKS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11414429-B2 | Compound or pharmaceutically acceptable salt thereof | RIKEN (JP) | 2022-08-16 | — | — | US | disclosed |
| US-11414429-B2 | Compound or pharmaceutically acceptable salt thereof | RIKEN (JP) | 2022-08-16 | — | — | US | disclosed |
| EP-3480198-B1 | NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | RIKEN (JP) | 2021-05-05 | — | — | EP | disclosed |
| US-20200172554-A1 | NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | RIKEN (JP) | 2020-06-04 | — | — | US | disclosed |
| US-20200172554-A1 | NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | RIKEN (JP) | 2020-06-04 | — | — | US | disclosed |
| EP-3480198-A1 | NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | RIKEN (JP) | 2019-05-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11414429-B2 | Compound or pharmaceutically acceptable salt thereof | DPP8, DPP7, AZI2 | POLB 2675/4885TNKS 3604/4885PARP1 1705/4885 |
| US-20200172554-A1 | NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | DPP8, DPP7, AZI2 | POLB 2991/4885TNKS 3690/4885PARP1 1906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.